The CANTOS (Canakinumab Anti-Inflammatory Thrombosis Outcomes Study) trial has provided strong evidence for the critical role of inflammation in atherosclerosis by showing that canakinumab—a human monoclonal anti-IL-1β antibody—led to a reduction in major cardiovascular events independent of lipid-level lowering [4]. The gene discussed is IL1B; the disease is atherosclerosis.